Dimethyltrienolone
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
| Identifiers | |
|
|
| Synonyms | RU-2420; 7α,17α-Dimethyltrenbolone; 7α,17α-Dimethyl-δ9,11-19-nortestosterone; 7α,17α-Dimethylestra-4,9,11-trien-17β-ol-3-one |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C20H26O2 |
| Molar mass | 298.4192 g/mol |
| 3D model (JSmol) | |
|
|
|
|
Dimethyltrienolone (developmental code name RU-2420) is a synthetic, orally active, extremely potent anabolic-androgenic steroid (AAS) and 17α-alkylated nandrolone (19-nortestosterone) derivative which was never marketed for medical use.[1] It has among the highest known affinity of any AAS for the androgen (and progesterone) receptors,[2][3] and has been said to be perhaps the most potent AAS to have ever been developed.[1]
Pharmacology[edit]
Dimethyltrienolone is an extremely potent agonist of the androgen and progesterone receptors and hence AAS and progestogen.[1] In animal bioassays, it was shown to possess more than 100 times the anabolic and androgenic potency of the reference AAS methyltestosterone.[1] The drug is not a substrate for 5α-reductase or aromatase and so is not potentiated in so-called "androgenic" tissues like the prostate gland or skin and does not have any estrogenic activity.[1] Due to its lack of estrogenicity, dimethyltrienolone has no propensity for causing estrogenic side effects like gynecomastia.[1] Because of its C17α methyl group and very high resistance to hepatic metabolism, dimethyltrienolone is said to be exceedingly hepatotoxic.[1]
Chemistry[edit]
Dimethyltrienolone, also known as 7α,17α-dimethyl-δ9,11-19-nortestosterone or as 7α,17α-dimethylestra-4,9,11-trien-17β-ol-3-one, as well as 7α,17α-dimethyltrenbolone, is a synthetic estrane steroid and a 17α-alkylated derivative of nandrolone (19-nortestosterone).[1] It is the 7α,17α-dimethyl derivative of trenbolone and the 7α-methyl derivative of metribolone,[4] as well as the δ9,11 analogue of metribolone and the δ9,11, 17α-methylated derivative of trestolone.[1]
History[edit]
Dimethyltrienolone was first described in 1967.[1][5]
See also[edit]
References[edit]
- ^ a b c d e f g h i j William Llewellyn (2009). Anabolics. Molecular Nutrition Llc. pp. 212–214. ISBN 978-0967930473.
- ^ Waszkowycz B, Clark DE, Frenkel D, Li J, Murray CW, Robson B, Westhead DR (1994). "PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores". J. Med. Chem. 37 (23): 3994–4002. PMID 7966160. doi:10.1021/jm00049a019.
- ^ Loughney DA, Schwender CF (1992). "A comparison of progestin and androgen receptor binding using the CoMFA technique". J. Comput. Aided Mol. Des. 6 (6): 569–81. PMID 1291626. doi:10.1007/bf00126215.
- ^ D. Ganten; D. Pfaff (6 December 2012). Actions of Progesterone on the Brain. Springer Science & Business Media. pp. 17–. ISBN 978-3-642-69728-9.
- ^ Mathieu, J (1967). Proceedings of the International Symposium on Drug Research, Montreal, Canada, June 12-14, 1967. Chemical Institute of Canada, Medical Chemistry Group, Montreal, Canada. p. 134.
